Select country change
Shopping cart (0 , 0,00 ) Menu Search
Distributed product

Glicentin Rat ELISA

  • Regulatory status:RUO
  • Type:Competitive ELISA, Immobilized antibody
  • Species:Rat
Please select your region to see available products and prices.
Cat. No. Size Price


RSCYK111R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Competitive ELISA, Immobilized antibody

Applications

Plasma-EDTA, Plasma-Heparin, Plasma-Citrate

Sample Requirements

30 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.206–50 pmol/ml

Intra-assay (Within-Run)

CV = 4.56 - 7.82

Inter-assay (Run-to-Run)

CV = 3.16 - 7.59

Spiking Recovery

Rat plasma A - 95,72% Rat plasma B - 92,34%

Summary

Research topic

Animal studies

Summary

Glicentin is a 69-amino-acid peptide containing glucagon and oxyntomodulin sequences in the molecule. It is
suggested that glicentin and oxyntomodulin are produced in the intestinal L-cells and glucagon in A-cells
in the pancreas, these peptides are derived from a common precursor by two different tissue-specific processing
pathways. In 1983, the amino acid sequence of human glicentin was deduced by Bell et al. from the genomic
sequence of human preproglucagon. Glicentin is a major form of gut glucagon-like immunoreactants (Gut GLIs).
In mammalian small intestine, proglucagon is processed into glicentin, oxyntomodulin, and glucagon -like peptide
1(GLP-1) and glucagon -like peptide 2 (GLP-2). GLP-1(7-37) and GLP-1(7-36)amide have been isolated from
the intestine and pancreas. It has been known that the GLP-1 sequence is well conserved between species in all
mammals studied. Using synthetic peptides, several investigators have demonstrated that in contrast to GLP-1 (1-37), truncated GLP-1(7-36)amide and GLP-1(7-37) have several physiological effects. However, the physiological role of glicentin, a major gut glucagon, is still unclear. It has been known that the circulating level of plasma glicentin-like peptides increases significantly nutrient ingestion. Yanaihara institute Inc. has succeeded in developing a specific and convenient EIA kit for determination of rat glicentin in plasma.

Product References (5)

References

  • Ishihara S, Fukuda R, Moriyama N, Ishimura N, Kaji T, Kushiyama Y, Amano K,Hirakawa K, Amano Y, Adachi K, Ashizawa N, Fukumoto S. Helicobacter pyloriinfection accelerates gene expression of glicentin in the gastric mucosa. Itsassociation with intestinal metaplasia of the stomach. Scand J Gastroenterol.1997 May;32(5):460-4. PubMed PMID: 9175207. See more on PubMed
  • Ohneda A, Kobayashi T, Nihei J. Effect of glicentin-related peptides onglucagon secretion in anaesthetized dogs. Diabetologia. 1986 Jun;29(6):397-401.PubMed PMID: 3527839. See more on PubMed
  • Ohneda A, Kobayashi T, Nihei J, Takahashi H. Effect of intraluminaladministration of amino acids upon plasma glicentin. Diabetes Res Clin Pract.1988 Oct 14;5(4):265-70. PubMed PMID: 3069408. See more on PubMed
  • Ohneda A, Ohneda K, Nagasaki T, Sasaki K. Insulinotropic action of humanglicentin in dogs. Metabolism. 1995 Jan;44(1):47-51. PubMed PMID: 7854165. See more on PubMed
  • Shibata C, Naito H, Jin XL, Ueno T, Funayama Y, Fukushima K, Hashimoto A,Matsuno S, Sasaki I. Effect of glucagon, glicentin, glucagon-like peptide-1 and-2 on interdigestive gastroduodenal motility in dogs with a vagally denervatedgastric pouch. Scand J Gastroenterol. 2001 Oct;36(10):1049-55. PubMed PMID:11589377. See more on PubMed
Related Products Docs